HealthQuill Clinical trials
Swedish-British AstraZeneca Plc’s medicine baxdrostat lowered blood pressure in trial patients during an end-stage study, and the company plans to file for regulatory approvals by the end of the year.
Drugs Health Pharma

AstraZeneca’s medicine lowers BP, to file for early approvals

Swedish-British AstraZeneca Plc’s medicine baxdrostat lowered blood pressure in trial patients during an end-stage study, and the company plans to file for regulatory.

Read More
Johnson & Johnson has stopped a mid-trial evaluation of a combination drug to treat people with a type of arthritis after the therapy failed to show “sufficient evidence” of benefit to the patients.
Drugs Health Pharma

J & J stops rheumatoid arthritis trial due to lack of ‘sufficient evidence’

Johnson & Johnson has stopped a mid-trial evaluation of a combination drug to treat people with a type of arthritis after the therapy.

Read More
The Food and Drug Administration has approved Pfizer Inc.’s treatment for metastatic non-small cell lung cancer.
Drugs Health

Implant TAR-200 eliminates bladder cancer in over 80% of high-risk cases in trials

HQ Team August 18, 2025: An implant called TAR-200 has shown remarkable results in treating high-risk bladder cancer. According to a recent Phase.

Read More
Bristol Myers Squibb, a New Jersey-based drugmaker, announced it has met its primary goal of improved overall survival for its investigational therapy to treat liver cancer.
Uncategorized

Bayer and Kumquat Biosciences ink $1.3 billion deal to develop cancer inhibitor

HQ Team August 13, 2025: Bayer and Kumquat Biosciences, a clinical-stage biotech, announced an exclusive global license and collaboration agreement worth $1.3 billion.

Read More
Jazz Pharmaceuticals Plc’s treatment for a rare and aggressive brain tumour that affects children and adults got approval from the US regulator.
Drugs Health Pharma

Jazz Pharma’s oral drug for a type of brain tumour gets US approval 

Jazz Pharmaceuticals Plc’s treatment for a rare and aggressive brain tumour that affects children and adults got approval from the US regulator.

Read More
AstraZeneca Plc’s therapy for a certain type of advanced lung cancer, in combination with chemotherapy, helped patients live longer, company data from an end-stage study reveals.
Drugs Health Pharma

AstraZeneca’s therapy for a type of lung cancer helps patients live longer 

HQ Team July 21, 2025: AstraZeneca Plc’s therapy for a certain type of advanced lung cancer, in combination with chemotherapy, helped patients live.

Read More
AbbVie Inc. and IGI Therapeutics SA have signed a $2 billion licensing agreement that gives AbbVie access to an antibody being tested for certain types of cancers and autoimmune conditions.
Drugs Health Pharma

AbbVie inks $2 billion deal with IGI, bags antibody to fight cancer 

HQ Team July 10, 2025: AbbVie Inc. and IGI Therapeutics SA have signed a $2 billion licensing agreement that gives AbbVie access to.

Read More
The US drug regulator has approved changes in the prescription of Eli Lilly’s drug Kisunla for treating adults with early Alzheimer’s disease, including those with mild memory problems or mild dementia.
Drugs Health Pharma

FDA permits slow dosing of Eli Lilly’s Alzheimer’s drug Kisunla

HQ Team July 9, 2025: The US drug regulator has approved changes in the prescription of Eli Lilly’s drug Kisunla for treating adults.

Read More
KalVista Pharmaceuticals Inc.'s medicine to treat hereditary angioedema, a rare disease that causes sudden and severe swelling attacks in the body, got approval from the US regulator. 
Drugs Health Pharma

KalVista’s oral pill for body swelling disorder gets US regulator’s nod 

HQ Team July 7, 2025: KalVista Pharmaceuticals Inc.’s medicine to treat hereditary angioedema, a rare disease that causes sudden and severe swelling attacks.

Read More
Novartis AG’s end-stage trial of a drug to treat the inflammation of arteries, which affects people aged over 50 years, has failed to meet its primary goal of being symptom-free after a year of therapy.
Drugs Health Pharma

Novartis’ drug to treat inflammation of arteries fails in end-stage trials

HQ Team July 3, 2025: Novartis AG’s end-stage trial of a drug to treat the inflammation of arteries, which affects people aged over.

Read More